Tagged with M

Remedica How do you explain that despite the Bolar exemption, a high number of scientists, a very educated population, and Europe’s lowest tax rate, Cyprus has never been able to attract FDI in either manufacturing or R&D? On the one hand, Cyprus seems an attractive place from a geographical and tax…

SIRO Clinpharm Pvt Ltd Undeniably, the landscape for CROs has dramatically changed compared to when you started in the 1990s. The idea of having India as a clinical research destination was not mature yet at that time. Has India reached that desired level of maturity today? India has indeed matured compared to when we…

Pharmaceutical Reearch Institute Would you start by giving our readers a brief outline of the history of the PRI? In 1952 the institute was established as a research and development (R&D) centre for the Polish pharmaceutical industry. In the 1960s the institute became part of what was known as the state-owned “Polfa” consortium…

Merck Russia Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago. Last year, we celebrated 110 years of company presence in this market! The Russian office was the third office that…

Boehringer Ingelheim Russia You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you have stayed with Boehringer Ingelheim throughout executive positions in Germany, Portugal, Ukraine, Finland, and, of course, now Russia. What has…

IMS Russia You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market? For the IMS, in terms of strategic development, this was certainly a significant acquisition—because afterwards, the organization became the leading…

Medicover You became president of the board at Medicover in Poland only a while ago and previously your previous experience was in high-profile management but not in healthcare. Do you now feel increased pressure being involved in a business where decisions take on a more ethical dimension? From a process perspective…

MSD Russia You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation prior to the interview, you mentioned that there has been a bit of a transition and adjustment period. How is…

Binnopharm Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established in 2006, but operations did not actually begin until 2009. JSFC Sistema is a company that often works in markets…

Nycomed Russia-CIS Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as strategically and economically unattractive. What have been the evolutions in the market that have made construction of a Russian facility…

Biocon If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage in an infrastructure deficient Bangalore. Both India and Biocon have come a long way since then. How different is the…

Boehringer Ingelheim India Pvt. Ltd. Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group, there are the mature and emerging markets for the prescription medicines. Within this structure, India falls into the emerging markets…